Financial comparisons Neurogene Inc.

Equities

Market Closed - Nasdaq Other stock markets 21:00:00 06/03/2026 GMT			5-day change	1st Jan Change
22.17 ^USD	+0.18%		-5.62%	+7.62%

03-03	Neurogene announces inducement grants under Nasdaq Listing Rule 5635(c)(4)	RE
02-26	Neurogene announces FDA breakthrough therapy designation for NGN-401 gene therapy for Rett syndrome	RE

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Revenues (N-1)	Net Margin (N-1)	EBIT Margin (N-1)	ROE (N-1)	ROA (N-1)	Leverage (N-1)
NEUROGENE INC.	925K	-8,123.68%	-8,930.27%	-	-	-
LONZA GROUP AG	7.25B	9.67%	17.9%	6.77%	3.48%	1.5x
BEONE MEDICINES AG	5.34B	5.37%	8.37%	11.07%	4.42%	-3.99x
CELLTRION, INC.	2.41B	11.88%	13.83%	2.46%	2.14%	1.28x
IQVIA HOLDINGS INC.	16.31B	8.34%	13.38%	32.9%	4.79%	3.63x
ASCENDIS PHARMA A/S	846M	-31.67%	-18.92%	-	-	1.57x
MEDPACE HOLDINGS, INC.	2.53B	17.83%	20.93%	70.23%	22.13%	-0.89x
EUROFINS SCIENTIFIC SE	8.57B	6.51%	14.79%	11.46%	4.17%	2.2x
IONIS PHARMACEUTICALS, INC.	944M	-40.36%	-40.47%	-69.35%	-9.5%	3.01x
TEMPUS AI, INC.	1.27B	-19.27%	-3.71%	-38.64%	-6.61%	-65.61x
QIAGEN N.V.	1.98B	4.23%	28.66%	13.31%	8.32%	0.34x
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	4.02B	-3.59%	19.77%	15.46%	6.99%	1.98x
ABIVAX	12.94M	-1,409.6%	-1,383.2%	-148.95%	-	0.4x
BIO-TECHNE CORPORATION	1.22B	6.02%	31.45%	15.37%	11.65%	0.43x
BLUEPRINT MEDICINES CORPORATION	509M	-13.19%	-41.67%	-31.26%	-21.6%	-0.14x
ICON PUBLIC LIMITED COMPANY	8.28B	9.56%	19.29%	12.39%	6.87%	1.66x
KYMERA THERAPEUTICS, INC.	39.21M	-794.04%	-891.07%	-28.49%	-18.41%	3.05x
Average	3.62B	-609.18%	-654.17%	-8.35%	1.34%	-3.10x
Weighted average by Cap.	5.29B	-75.59%	-72.02%	1.49%	2.82%	-1.51x